Spotlight On... FDA nod for Hologic breast biopsy system that offers 3-D image guidance; ODH, Watson Health launch behavioral population health tool; First robotic exoskeleton meta-analysis released; and more...

Hologic ($HOLX) said the FDA cleared its Affirm prone biopsy system, which it said is the first dedicated prone system to offer both 2-D and 3-D imaging-guided breast biopsies. The company said that it has already launched the system, which is expected to enable radiologists to better target lesions found during 3-D mammography exams and other types of screening. "The launch of our Affirm prone biopsy system is the most significant advancement in prone biopsy technology since we introduced the first system more than 20 years ago," said Pete Valenti, Hologic's division president for breast and skeletal health solutions, in a statement. "We identified a need for a minimally invasive, stereotactic breast biopsy technology that marries the advances in 3-D mammography exams with the prone positioning many doctors prefer and are excited to bring this new generation prone biopsy system to market." More

@FierceMedDev: NEA-backed startup wins positive FDA panel vote for the first synthetic cartilage implant. Report | Follow @FierceMedDev

@EmilyWFierce: $NVO is planning to spend $110M to expand its production facilities in France. FiercePharmaManufacturing story | Follow @EmilyWFierce

@amirahalidrus: Stryker augments Spine business with BD vertebral compression fracture acquisition. More | Follow @amirahalidrus

> Behavioral health analytics provider ODH and IBM Watson Health ($IBM) have launched a population health management platform, Mentrics, to help managed care organizations improve quality and reduce the cost of health care for patients with chronic and mental health conditions that have a significant behavioral component. More

> The first meta-analysis of robotic exoskeleton studies finds that roughly three-quarters of 111 patients studied in 12 trials were able to walk independently without human assistance. More

> Juvent had results for its Dynamic Motion Therapy Platform in pediatric cancer survivors reported in the Journal of the American Medical Association Oncology that showed an 11% increase in bone density. More

Read more on